Mothers against decapentaplegic homolog family protein (SMAD) (SMAD)

The SMAD family member proteins are essential intracellular mediators of the transforming growth factor-beta (TGF-beta) signaling superfamily, which includes TGF-betas, bone morphogenetic proteins (BMPs), and activins [1][2]. These proteins are categorized into three functional groups: receptor-regulated SMADs (R-SMADs: SMAD1, 2, 3, 5, and 8/9), common-partner SMADs (Co-SMAD: SMAD4), and inhibitory SMADs (I-SMADs: SMAD6 and 7) [2][3]. Upon ligand binding to cell surface receptors, R-SMADs are phosphorylated, form a heteromeric complex with SMAD4, and translocate into the nucleus to act as transcription factors that regulate genes involved in cell growth, differentiation, and development [1][4]. In many cancers, particularly pancreatic and colorectal, SMAD4 acts as a tumor suppressor and is frequently lost or mutated, leading to uncontrolled proliferation [5]. Conversely, in fibrotic diseases, overactivation of the SMAD3 pathway drives the excessive production of extracellular matrix components [6]. Pharmacological targeting of the SMAD pathway is an active area of research, focusing on small molecule inhibitors like SIS3 that target specific SMAD phosphorylation or antisense oligonucleotides to reduce expression [7]. However, the pathway's broad biological roles in homeostasis necessitate careful management of off-target systemic effects and potential paradoxical effects in cancer progression [8].

Other names

MADHMAD homologMothers against DPP homologSMAD family

Inhibition of SMAD phosphorylation, inhibition of SMAD-SMAD complex formation, or inhibition of nuclear translocation.